Clinical Trial Update: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) [Phase 2]

View source ↗

Summary

A Phase 2 pediatric trial is evaluating adding dasatinib or venetoclax to initial therapy to improve responses in newly diagnosed T-cell acute lymphoblastic leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Phenotype Acute Leukemia
• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoma

Drugs mentioned

• Sprycel (dasatinib)
• Venclexta (venetoclax)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma | Phase 2 | Status: RECRUITING